Park KS - Search Results

1

TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2.

Park KS, Kim DS, Ko C, Lee SJ, Oh SH, Kim SY. Park KS, et al. Front Biosci (Elite Ed). 2011 Jan 1;3(1):341-54. doi: 10.2741/e249. Front Biosci (Elite Ed). 2011. PMID: 21196314 Free article.

2

Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.

Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY. Kim DS, et al. Among authors: park ks. Cancer Lett. 2009 Jan 18;273(2):243-9. doi: 10.1016/j.canlet.2008.08.015. Epub 2008 Sep 19. Cancer Lett. 2009. PMID: 18804908

3

A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells.

Kim JM, Voll RE, Ko C, Kim DS, Park KS, Kim SY. Kim JM, et al. Among authors: park ks. J Mol Biol. 2008 Dec 26;384(4):756-65. doi: 10.1016/j.jmb.2008.10.010. Epub 2008 Oct 11. J Mol Biol. 2008. PMID: 18950638

4

Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues.

Park KS, Kim DS, Jeong KC, Kim SY. Park KS, et al. Front Biosci (Landmark Ed). 2009 Jan 1;14(5):1945-51. doi: 10.2741/3354. Front Biosci (Landmark Ed). 2009. PMID: 19273176 Free article.

5

Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors.

Kim DS, Park KS, Kim SY. Kim DS, et al. Among authors: park ks. Front Biosci (Landmark Ed). 2009 Jan 1;14(7):2514-21. doi: 10.2741/3394. Front Biosci (Landmark Ed). 2009. PMID: 19273216 Free article.

6

I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway.

Kim DS, Han BG, Park KS, Lee BI, Kim SY, Bae CD. Kim DS, et al. Among authors: park ks. Biochem Biophys Res Commun. 2010 Aug 20;399(2):300-6. doi: 10.1016/j.bbrc.2010.07.078. Epub 2010 Jul 24. Biochem Biophys Res Commun. 2010. PMID: 20659425

7

Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells.

Park KS, Han BG, Lee KH, Kim DS, Kim JM, Jeon H, Kim HS, Suh SW, Lee EH, Kim SY, Lee BI. Park KS, et al. Cancer Lett. 2009 Feb 18;274(2):201-7. doi: 10.1016/j.canlet.2008.09.007. Epub 2008 Oct 11. Cancer Lett. 2009. PMID: 18851895

8

Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.

Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM. Park KS, et al. Among authors: park sy. J Cancer Res Clin Oncol. 2010 Apr;136(4):493-502. doi: 10.1007/s00432-009-0681-6. Epub 2009 Sep 18. J Cancer Res Clin Oncol. 2010. PMID: 19763620

9

Proteomic analysis of high-molecular-weight protein polymers in a doxorubicin-resistant breast-cancer cell line.

Park SS, Kim DS, Park KS, Song HJ, Kim SY. Park SS, et al. Among authors: park ks. Proteomics Clin Appl. 2007 Jun;1(6):555-60. doi: 10.1002/prca.200700122. Epub 2007 May 11. Proteomics Clin Appl. 2007. PMID: 21136706

10

Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer.

Choi CM, Jang SJ, Park SY, Choi YB, Jeong JH, Kim DS, Kim HK, Park KS, Nam BH, Kim HR; Korean Thoracic Oncology Research Group (KTORG); Kim SY, Hong KM. Choi CM, et al. Among authors: park ks, park sy. Mol Cancer. 2011 Sep 24;10:119. doi: 10.1186/1476-4598-10-119. Mol Cancer. 2011. PMID: 21943122 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,513 results

Search Page

Filters